greeksoup/ stock research

Solid Power, Inc.: Q4 FY2025 earnings call

What management said about Q4 FY2025, from the documents filed with the SEC on 24 February 2026: press release. Guidance figures: 1 new, 1 kept. The quarter’s numbers.

Key takeaways

  • Revenue rose on SK On work: Total revenue and grant income was $21.7 million, up from $20.1 million. Product revenue was $17.9 million and grant income was $3.8 million, against no grant income in 2024. Source
  • Net loss narrowed to $93.4 million: Net loss was $93.4 million, or $0.51 per share, against $96.5 million, or $0.54 per share, in 2024. Operating loss was $100.8 million, compared with $105.3 million. Source
  • Samsung SDI and BMW evaluation agreement: The company announced a Joint Evaluation Agreement with Samsung SDI and BMW to develop all-solid-state batteries, which it said validates its electrolyte sampling efforts. Source
  • Electrolyte pilot line due end-2026: Detailed design for a continuous electrolyte production pilot line was conducted. Management expects to install and commission the line by the end of 2026. Source
  • Total liquidity rose to $336.5 million: Total liquidity was $336.5 million at December 31, 2025, up $9.0 million from a year earlier. Cash and cash equivalents were $21.6 million and available-for-sale securities were $314.8 million. Source
  • Final 2025 cash investment at lower end: The final 2025 cash investment, covering operations and capital expenditures, was $84.5 million. The company said it came in at the lower end of the revised guidance. Source
  • $130 million registered direct offering in January: The company completed a $130 million registered direct offering in January 2026, after the year-end, according to the release. Source

“We advanced our electrolyte technology and executed on our roadmap toward scalable production.”

John Van Scoter, President and Chief Executive Officer

Guidance

AreaPeriodFigureAgainst last quarter
Cash investment (cash used in operations and capital expenditures) Source2026$85 million to $100 millionNew
Electrolyte continuous pilot line, installation and commissioning Source2026by the end of 2026Kept

What changed from last quarter

  • New guidance: A 2026 cash investment range of $85 million to $100 million was given. No 2026 cash investment range appears in the prior-quarter release. Source
  • Guidance kept: Pilot line commissioning remains a 2026 expectation. The prior-quarter release said commissioning was on track for 2026.
  • New: The company completed a $130 million registered direct offering in January 2026, after the year-end. Source
  • New: The 2026 objectives add exploring potential partnerships for commercial-scale electrolyte production. The prior-quarter objectives did not include this item. Source

Results and growth drivers

  • Revenue rose on SK On work: Total revenue and grant income was $21.7 million, up from $20.1 million. Product revenue was $17.9 million and grant income was $3.8 million, against no grant income in 2024. Source
  • Net loss narrowed to $93.4 million: Net loss was $93.4 million, or $0.51 per share, against $96.5 million, or $0.54 per share, in 2024. Operating loss was $100.8 million, compared with $105.3 million. Source
  • Interest income declined year on year: Interest income was $13.2 million, down from $17.7 million. Warrant liability fair value changes were a $5.1 million charge, against $4.5 million in 2024. Source

Partner programs and milestones

  • Samsung SDI and BMW evaluation agreement: The company announced a Joint Evaluation Agreement with Samsung SDI and BMW to develop all-solid-state batteries, which it said validates its electrolyte sampling efforts. Source
  • SK On line near site acceptance: Factory acceptance testing under the SK On line installation agreement is complete. Site acceptance testing at SK On's facility is nearing completion. Source
  • Electrolyte pilot line due end-2026: Detailed design for a continuous electrolyte production pilot line was conducted. Management expects to install and commission the line by the end of 2026. Source
  • BMW i7 test vehicle featured cells: Management cited BMW's introduction of an i7 test vehicle featuring the company's cells and solid-state battery technology as a partner development in 2025. Source
  • Electrolyte performance work continued: Management said electrolyte innovation and performance work used internal feedback and customer input to drive expected improvements. Source

“This funding surpassed our initial expectations and serves to strengthen our financial position, extend our runway, and support advancement of our electrolyte technology and progress toward commercialization.”

John Van Scoter, President and Chief Executive Officer

Operating costs and expenses

  • Operating expenses fell to $122.6 million: Operating expenses were $122.6 million, compared with $125.5 million in 2024. Management attributed the spending to research and development and to equipment and services for the SK On agreements. Source
  • R&D and SG&A line items: Research and development was $72.5 million, against $73.3 million in 2024. Selling, general and administrative expense was $29.4 million, against $31.8 million. Source
  • Stock compensation and warrant charge: Stock-based compensation expense was $9.0 million, down from $12.0 million. The warrant liability fair value change was a $5.1 million charge, against $4.5 million in 2024. Source

Liquidity and cash use

  • Total liquidity rose to $336.5 million: Total liquidity was $336.5 million at December 31, 2025, up $9.0 million from a year earlier. Cash and cash equivalents were $21.6 million and available-for-sale securities were $314.8 million. Source
  • Final 2025 cash investment at lower end: The final 2025 cash investment, covering operations and capital expenditures, was $84.5 million. The company said it came in at the lower end of the revised guidance. Source
  • Pilot line capital spending in 2025: Capital expenditures were $10.2 million in 2025, mainly for planned construction of the continuous electrolyte production pilot line. Source
  • Year-end contract assets and current liabilities: Contract assets and receivables were $9.6 million and total current liabilities were $16.8 million at December 31, 2025. Source

“In 2026, we will continue to drive toward commercialization of our ASSB technology.”

John Van Scoter, President and Chief Executive Officer

Equity raising and share count

  • ATM raised $88.8 million net in 2025: The at-the-market program raised $56.0 million of net proceeds in the fourth quarter. For full-year 2025 the program's net proceeds were $88.8 million. Source
  • Two ATM net proceeds figures reported: The highlights section cites $89.4 million of net ATM proceeds for 2025, which differs from the $88.8 million given in the financial discussion. Source
  • $130 million registered direct offering in January: The company completed a $130 million registered direct offering in January 2026, after the year-end, according to the release. Source
  • Shares outstanding rose to 201.2 million: Shares issued and outstanding were 201,181,175 at December 31, 2025, up from 180,364,028 a year earlier. Source
  • Share repurchases fell to $3.6 million: Repurchases of common stock were $3.6 million in 2025, compared with $9.1 million in 2024. Source

Strategy and 2026 objectives

  • 2026 objectives center on partners: Objectives for 2026 include strengthening partner relationships and continuing the electrolyte development roadmap, alongside financial discipline and technology investment. Source
  • Business model sells electrolyte, licenses designs: The company describes its model as selling electrolyte to cell manufacturers and licensing its cell designs and manufacturing processes, which it says distinguishes it from many competitors. Source
  • Electrolyte product competitiveness focus: A 2026 objective is to promote electrolyte product competitiveness, using the Electrolyte Innovation Center and cell research and development. Source

Coming up, as management said on 24 February 2026

  • Electrolyte pilot line due end-2026: Management expects to install and commission the continuous electrolyte production pilot line by the end of 2026. Source
  • SK On site acceptance testing completion: Site acceptance testing at SK On's facility is nearing completion, following completed factory acceptance testing. Source
  • Partnerships for commercial electrolyte production: The 2026 plan includes exploring potential partnerships for commercial-scale electrolyte production. Source

Earlier plans management reported on

  • On track: The prior-quarter release said commissioning of the continuous electrolyte pilot line was on track for 2026. The full-year release gives end-2026 timing.
  • Met: Management said the 2025 cash investment of $84.5 million came in at the lower end of the revised guidance. Source
  • On track: The prior-quarter release said site acceptance testing for the SK On pilot cell line remained on schedule for completion by year-end.

Other quarters

Summarised with AI from the documents the company filed with the SEC. Every point is checked against the filing before it is shown: management’s own words word for word, figures against the line or table row they come from. A point that fails the check is left out. Source opens the filing at that line.